These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10099965)

  • 1. A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study.
    Dada T; Salha O; Baillie HS; Sharma V
    Hum Reprod; 1999 Feb; 14(2):288-93. PubMed ID: 10099965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study.
    El-Nemr A; Bhide M; Khalifa Y; Al-Mizyen E; Gillott C; Lower AM; Al-Shawaf T; Grudzinskas JG
    Eur J Obstet Gynecol Reprod Biol; 2002 Jul; 103(2):140-5. PubMed ID: 12069736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
    Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
    Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.
    Lockwood GM; Pinkerton SM; Barlow DH
    Hum Reprod; 1995 Feb; 10(2):293-8. PubMed ID: 7769051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of three GnRH analogues in an IVF programme.
    Weissman A; Barash A
    Hum Reprod; 2000 Feb; 15(2):493-5. PubMed ID: 10655330
    [No Abstract]   [Full Text] [Related]  

  • 6. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.
    Maheshwari A; Gibreel A; Siristatidis CS; Bhattacharya S
    Cochrane Database Syst Rev; 2011 Aug; (8):CD006919. PubMed ID: 21833958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
    Albuquerque LE; Saconato H; Maciel MC
    Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.
    Goldman JA; Dicker D; Feldberg D; Ashkenazi J; Voliowich I
    Hum Reprod; 1994 Feb; 9(2):226-8. PubMed ID: 8027276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of two gonadotropin-releasing hormone (GnRH) analogues (leuprolide and buserelin) in short and long protocols for assisted reproduction techniques.
    Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Pados G; Mantalenakis S
    J Assist Reprod Genet; 1994 Feb; 11(2):85-91. PubMed ID: 7819707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: a prospective clinical trial.
    Avrech OM; Goldman GA; Pinkas H; Amit S; Neri A; Zukerman Z; Ovadia J; Fisch B
    Gynecol Endocrinol; 1996 Jun; 10(3):165-70. PubMed ID: 8862491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of buserelin and nafarelin in IVF cycles and in subsequent frozen-thawed embryo transfer cycles.
    Simberg N; Tulppala M; Husa LM; Tiitinen A
    Acta Obstet Gynecol Scand; 1998 Sep; 77(8):854-9. PubMed ID: 9776601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafarelin acetate for pituitary suppressions in in-vitro fertilisation cycles--a Singaporean experience.
    Loh SK; Leong NK
    Singapore Med J; 1999 Dec; 40(12):752-5. PubMed ID: 10709427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WITHDRAWN: Gonadotrophin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles.
    Daya S
    Cochrane Database Syst Rev; 2007 Jul; (1):CD001299. PubMed ID: 17636664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial.
    Penzias AS; Shamma FN; Gutmann JN; Jones EE; DeCherney AH; Lavy G
    Obstet Gynecol; 1992 May; 79(5 ( Pt 1)):739-42. PubMed ID: 1533022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-control study on reduced-dose depot versus daily administration of gonadotrophin-releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles.
    Gao J; Xu YW; Miao BY; Zhou CQ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1901-6. PubMed ID: 25056469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantation and pregnancy rates in relation to oestradiol and progesterone profiles in cycles with and without the use of gonadotrophin-releasing hormone agonist suppression.
    Hassiakos D; Toner JP; Muasher SJ; Jones HW
    Hum Reprod; 1990 Nov; 5(8):1004-8. PubMed ID: 2127937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
    Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
    Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis.
    Wong JM; Forrest KA; Snabes SZ; Zhao SZ; Gersh GE; Kennedy SH
    Hum Reprod Update; 2001; 7(1):92-101. PubMed ID: 11212082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
    Borm G; Mannaerts B
    Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.